| Survival: | 8.2 months |
| Toxicity Grade: | 4 |
| Treatments: | Chemotherapy |
| Drugs: | Temodar |
| Country: | Netherlands |
| City/State/Province: | Rotterdam |
| Hospital: | Erasmus Medical Center |
| Journal: | Link |
| Date: | 4/2002 |
| Description: |
| Patients: This Phase II study involved 27 patients with malignant pleural mesothelioma. None of these patients had been administered prior chemotherapy. Treatment: The treatment consisted of the chemotherapy drug, temozolomide (temodar). Toxicity: Grade 3-4 toxicities included hematologic, infection, nausea, vomiting, and arthralgia. Results: The median overall survival from the time the patient registered in the study was 8.2 months. Support: Schering-Plough International supported this study. Schering-Plough markets temodar. Correspondence: J.P. van Meerbeeck |